Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 4/20 | 0.38 |
| ▸ | CA1 | P00915 | 4/20 | 0.38 |
| ▸ | CA2 | P00918 | 4/20 | 0.38 |
| ▸ | CA9 | Q16790 | 4/20 | 0.38 |
| ▸ | TYMP | P19971 | 1/20 | 0.38 |
| ▸ | TK1 | P04183 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6837658 | 0.89 | MAPK1 (0.40) | KMT2AMAPK1HPGDTYMPTK1 | |
| SCHEMBL14542978 | 0.84 | MAPK1 (0.40) | MAPK1HPGDCA12CA1CA2 | |
| SCHEMBL16297679 | 0.84 | MAPK1 (0.40) | MAPK1HPGDCA12CA1CA2 | |
| SCHEMBL7550172 | 0.84 | TK1 (0.39) | KMT2AMAPK1HPGDTK1 | |
| SCHEMBL3918737 | 0.83 | TK1 (0.40) | MAPK1HPGDCA12CA1CA2 | |
| SCHEMBL7761597 | 0.83 | HPGD (0.41) | MAPK1HPGDCA12CA1CA2 | |
| SCHEMBL8045900 | 0.81 | TK1 (0.46) | MAPK1HPGDCA12CA1CA2 | |
| SCHEMBL6837969 | 0.79 | TYMP (0.41) | KMT2AMAPK1HPGDTYMPTK1 | |
| SCHEMBL6837655 | 0.78 | TYMP (0.43) | KMT2AMAPK1HPGDTYMPTK1 | |
| SCHEMBL28985698 | 0.74 | MAPK1 (0.49) | KMT2AMAPK1HPGDTYMPTK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7485421-B2 | Polyamide-oligonucleotide derivatives, their preparation and use | HOECHST GMBH (DE) | 2009-02-03 | — | — | US | disclosed |
| EP-1113021-B1 | Polyamide-oligonucleotide derivatives, their production and use | SANOFI AVENTIS DEUTSCHLAND (DE) | 2006-08-09 | — | — | EP | disclosed |
| US-20050026817-A1 | Polyamide-oligonucleotide derivatives, their preparation and use | AVENTIS PHARMA DEUTSCHLAND GMBH (US) | 2005-02-03 | — | — | US | disclosed |
| US-6756199-B1 | USED FOR THE SYNTHESIS OF BOTH PREDEFINED AND RANDOM SEQUENCE PEPTIDE NUCLEIC ACID OLIGOMERS | ISIS PHARMACEUTICALS, INC. | 2004-06-29 | — | — | US | disclosed |
| EP-0672677-B1 | Polyamide-oligonucleotide derivatives, their production and use | AVENTIS PHARMA GMBH (DE) | 2002-07-03 | — | — | EP | disclosed |
| EP-0761681-B1 | Process for the preparation of substituted derivatives of N-ethylglycine | HOECHST AG (DE) | 2002-03-13 | — | — | EP | disclosed |
| EP-1113021-A2 | Polyamide-oligonucleotide derivatives, their production and use | Aventis Pharma Deutschland GmbH (DE) | 2001-07-04 | — | — | EP | disclosed |
| US-6204326-B1 | ADDING PEPTIDE NUCLEIC ACID UNITS TO AN AMINE TERMINATED PEPTIDE NUCLEIC ACID OLIGOMER ON A SOLID PHASE SYNTHETIC RESIN; BIOSYNTHESIS | ISIS PHARMACEUTICALS, INC. | 2001-03-20 | — | — | US | disclosed |
| US-6169169-B1 | SHORT, SPECIES SPECIFIC, PEPTIDE NUCLEIC ACID HYBRIDIZATION PROBES FOR DIAGNOSIS OF UROGENITAL DISORDERS; HAVING N-(2-AMINOETHYL)GLYCINE UNITS IN AMIDE LINKAGE WITH THE GLYCINE NITROGEN CONNECTED TO NUCLEOBASES | DAKO A/S (DK) | 2001-01-02 | — | — | US | disclosed |
| US-6121418-A | PNA synthesis using a base-labile amino protecting group | HOECHST AKTIENGESELLSCHAFT (DE) | 2000-09-19 | — | — | US | disclosed |
| EP-0777678-A1 | PNA COMBINATORIAL LIBRARIES AND IMPROVED METHODS OF SYNTHESIS | ISIS PHARMACEUTICALS, INC. (US) | 1997-06-11 | — | — | EP | disclosed |
| EP-0761681-A2 | Process for the preparation of substituted derivatives of N-ethylglycine | HOECHST AKTIENGESELLSCHAFT (DE) | 1997-03-12 | — | — | EP | disclosed |
| EP-0760008-A1 | PNA PROBES FOR DETECTION OF NEISSERIA GONORRHOEAE AND CHLAMYDIA TRACHOMATIS | DAKO A/S (DK) | 1997-03-05 | — | — | EP | disclosed |
| US-5539083-A | FROM HALOACETYL HALIDE OR SULFONYLACETYL HALIDE, PROTECTED ALKYLENEDIAMINE, AND A DERIVATIVE OF A NUCLEIC ACID BASE | ISIS PHARMACEUTICALS, INC. (US) | 1996-07-23 | — | — | US | disclosed |
| WO-1995032305-A1 | PNA PROBES FOR DETECTION OF NEISSERIA GONORRHOEAE AND CHLAMYDIA TRACHOMATIS | DAKO A/S (DK) | 1995-11-30 | — | — | WO | disclosed |
| EP-0672661-A1 | Substituted N-ethyl-glycinderivatives for the preparation of PNA and PNA-/DNA hybrides | HOECHST AKTIENGESELLSCHAFT (DE) | 1995-09-20 | — | — | EP | disclosed |
| EP-0672701-A1 | PNA-synthesis using a base labile aminoprotecting group | HOECHST AKTIENGESELLSCHAFT (DE) | 1995-09-20 | — | — | EP | disclosed |
| EP-0672677-A2 | Polyamide-oligonucleotide derivatives, their production and use | HOECHST AKTIENGESELLSCHAFT (DE) | 1995-09-20 | — | — | EP | disclosed |
| EP-0672700-A1 | PNA-synthesis using an aminoprotecting group which is labile against weak acids | HOECHST AKTIENGESELLSCHAFT (DE) | 1995-09-20 | — | — | EP | disclosed |
| WO-1995023163-A1 | PNA COMBINATORIAL LIBRARIES AND IMPROVED METHODS OF SYNTHESIS | ISIS PHARMACEUTICALS, INC. (US) | 1995-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026817-A1 | Polyamide-oligonucleotide derivatives, their preparation and use | POLRMT, POLR2H, POLN | KMT2A 2106/4885MAPK1 3965/4885HPGD 3786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.